Measurable residual disease assessment and allogeneic transplantation as consolidation therapy in adult acute lymphoblastic leukemia in Colombia [documento electrónico] / Marcos Arango Barrientos, ; Laura María Díaz Correa,  . - 2020.
Obra : Clinical Lymphoma, Myeloma & Leukemia

Idioma : Inglés (eng)

Palabras clave :	Acute lymphoblastic leukemia  Disease free survival  Hematopoietic stem-cell transplantation  Measurable residual disease  Prognosis
Resumen :	Introduction: Detectable minimal residual disease (MRD) after therapy for acute lymphoblastic leukemia (ALL) is the strongest predictor of hematologic relapse. The objective of the study was to assess disease-free survival (DFS) and overall survival (OS) of patients with ALL according with MRD status at the end of induction therapy in a Colombian population. Patients and Methods: We assessed a retrospective cohort to compare DFS and OS in adults with de novo ALL according to MRD status at the end of induction chemotherapy, and the type of postinduction consolidation strategy used. Results: A total of 165 adults with ALL were included in the MRD part of the study, 73 patients in the MRD-negative group and 92 in the MRD-positive group. Median DFS for the MRD-positive group was 11 months (95% confidence interval, 11.7-22.2) and was not reached for the MRD-negative group ( P
Mención de responsabilidad :	Juan Felipe Combariza, Marcos Arango, Laura Díaz, Claudia Agudelo, Sonia Hernandez, Ana María Madera, Guillermo León, Vladimir Avila, Leonardo Bautista, Jaime Valdés, Rocio Orduz, Fabian Mejía, Liliana Moreno y Carlos Ramirez
Referencia :	Clin Lymphoma Myeloma Leuk. 2021 Apr;21(4):e365-e372.
DOI (Digital Object Identifier) :	10.1016/j.clml.2020.11.010
PMID :	33277225
En línea :	https://linkinghub.elsevier.com/retrieve/pii/S2152-2650(20)30634-0
Enlace permanente :	https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5187